Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Miransertib||Phase I||Actionable||In a Phase I trial, Miransertib (ARQ092) demonstrated safety and is currently being tested for efficacy in clinical trials in patients with advanced solid tumors (American Association for Cancer Research. April 6-10, 2013. Abstract #LB-197).||detail...|
|PubMed Id||Reference Title||Details|
|First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts||Full reference...|